- Email: [email protected]
Toward genomic cell culture engineering via physiological fundamentals
Journal of Biotechnology 136S (2008) S114–S117
Contents lists available at ScienceDirect
Journal of Biotechnology journal homepage: www.elsevier.com/locate/jbiotec
Abstracts
Section II Tissue engineering and cell cultivation
KN-018
KN-019
Biotechnology of mammalian cells
Toward genomic cell culture engineering via physiological fundamentals
Daniel I.C. Wang Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, United States E-mail address: [email protected]. The use of animal cells in the production of biopharmaceuticals has been seen to be the major avenue for the biotechnology and pharmaceutical industries in recent years. At this time, the total revenue of biopharmaceuticals produced by animal cells including vaccines is in excess of US $50 billion dollars per year. In addition, in the year 2007, it was reported over 30 new biopharmaceutical products from animal cell culture have been approved through Phase III clinical trials. Today, there are over 350 animal cell products in various phases of clinical trials. There is every indication that the use of cell culture will continue to increase in the future. This presentation will first review the status of biotechnology in the USA. Within the scope of this presentation, the past achievements that have been developed in cell culture will be highlighted. These include enabling technologies that have been developed for the advancements in cell culture. In addition, scientific and technological achievements in research, development and manufacturing using cell culture will also be presented. In the years to come, there is the prediction that the biopharmaceutical products from cell culture will be used for treatment of chronic human diseases in contrast to the past where the major biopharmaceutical products have be used in acute disease treatment. This translates to increased amount of product needed and lower cost for manufacturing. This would mean that the manufacturing process for the future would have to be different in comparison to the past. This would also mean that there would be scientific and technological challenges in the days to come. This presentation will highlight these technical challenges where research and development opportunities for universities and industry can be anticipated. doi:10.1016/j.jbiotec.2008.07.368
0168-1656/$ – see front matter
Wei-Shou Hu Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455, USA Protein therapeutics produced by recombinant mammalian cells have greatly enhanced health care in the past two decades. At the heart of the technology is the incredible capability of host cells in producing high quality product at levels that rival professional protein secretors in vivo. Such hyperproductivity is a composite of many superior characteristics, including resilience in growth, enhanced cellular machinery related to protein synthesis and secretion, as well as alteration in many respects of cellular homeostasis. In the next phase of technological development processes that generate those products at even higher efficiency will make those therapeutics affordable to greater populations around the world. The development of such processes will likely take advantage of recent advances in genomics and cell engineering. Genomic tools have been applied to characterize cellular responses to favorable process conditions and to elucidate hyperproductivity traits of production cell lines. Moreover, in the past few years the importance of metabolic traits on growth kinetics of producing cells is better realized. Importantly our understanding of the regulation of metabolism and its relation in the cell growth control network has also been greatly enhanced. The insights gained from such studies have enabled us to identify key areas of genetic and process manipulations for further advancing therapeutic protein technology. Riding on these advances cell culture engineering can propel the technology to further benefit the society in the coming years. doi:10.1016/j.jbiotec.2008.07.369
Contents lists available at ScienceDirect
Journal of Biotechnology journal homepage: www.elsevier.com/locate/jbiotec
Abstracts
Section II Tissue engineering and cell cultivation
KN-018
KN-019
Biotechnology of mammalian cells
Toward genomic cell culture engineering via physiological fundamentals
Daniel I.C. Wang Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, United States E-mail address: [email protected]. The use of animal cells in the production of biopharmaceuticals has been seen to be the major avenue for the biotechnology and pharmaceutical industries in recent years. At this time, the total revenue of biopharmaceuticals produced by animal cells including vaccines is in excess of US $50 billion dollars per year. In addition, in the year 2007, it was reported over 30 new biopharmaceutical products from animal cell culture have been approved through Phase III clinical trials. Today, there are over 350 animal cell products in various phases of clinical trials. There is every indication that the use of cell culture will continue to increase in the future. This presentation will first review the status of biotechnology in the USA. Within the scope of this presentation, the past achievements that have been developed in cell culture will be highlighted. These include enabling technologies that have been developed for the advancements in cell culture. In addition, scientific and technological achievements in research, development and manufacturing using cell culture will also be presented. In the years to come, there is the prediction that the biopharmaceutical products from cell culture will be used for treatment of chronic human diseases in contrast to the past where the major biopharmaceutical products have be used in acute disease treatment. This translates to increased amount of product needed and lower cost for manufacturing. This would mean that the manufacturing process for the future would have to be different in comparison to the past. This would also mean that there would be scientific and technological challenges in the days to come. This presentation will highlight these technical challenges where research and development opportunities for universities and industry can be anticipated. doi:10.1016/j.jbiotec.2008.07.368
0168-1656/$ – see front matter
Wei-Shou Hu Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455, USA Protein therapeutics produced by recombinant mammalian cells have greatly enhanced health care in the past two decades. At the heart of the technology is the incredible capability of host cells in producing high quality product at levels that rival professional protein secretors in vivo. Such hyperproductivity is a composite of many superior characteristics, including resilience in growth, enhanced cellular machinery related to protein synthesis and secretion, as well as alteration in many respects of cellular homeostasis. In the next phase of technological development processes that generate those products at even higher efficiency will make those therapeutics affordable to greater populations around the world. The development of such processes will likely take advantage of recent advances in genomics and cell engineering. Genomic tools have been applied to characterize cellular responses to favorable process conditions and to elucidate hyperproductivity traits of production cell lines. Moreover, in the past few years the importance of metabolic traits on growth kinetics of producing cells is better realized. Importantly our understanding of the regulation of metabolism and its relation in the cell growth control network has also been greatly enhanced. The insights gained from such studies have enabled us to identify key areas of genetic and process manipulations for further advancing therapeutic protein technology. Riding on these advances cell culture engineering can propel the technology to further benefit the society in the coming years. doi:10.1016/j.jbiotec.2008.07.369